N/A
Completed N=419
Daily Use of JARDIANCE® Tablets in Japanese Elderly Patients With Type 2 Diabetes Mellitus
Source: ClinicalTrials.gov NCT02367131 ↗Enrolled (actual)
419
Serious AEs
1.5%
Results posted
Jun 2018
Primary outcomePrimary: Percentage of Patients With Adverse Drug Reactions (ADRs) — 20.53 Percentage of participants
Summary
Study to investigate the safety and efficacy of daily use of JARDIANCE® Tablets in Japanese elderly patients with type 2 diabetes mellitus.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Patients With Adverse Drug Reactions (ADRs) |
20.53 | — |
| SECONDARY Change From Baseline in HbA1c (%) at the Last Observation During the Observation Period |
-0.36 | — |
| SECONDARY Change From Baseline in Fasting Plasma Glucose at the Last Observation During the Observation Period |
-8.4 | — |
Eligibility Criteria
Inclusion criteria
Male and female elderly patients (age 65 and over) with type 2 diabetes mellitus who have never been treated with JARDIANCE® Tablets before the enrolment and start taking JARDIANCE® Tablets within 3 months after launch in Japan
Exclusion criteria
None
Data sourced from ClinicalTrials.gov (NCT02367131). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.